RESEARCH

PharmAbcine to Present Updated Interim Data from the Ongoing Phase Ib Trial of Olinvacimab and Pembrolizumab Combination Therapy

PharmAbcine | December 08, 2020

PharmAbcine Inc., a clinical-stage biotech organization focusing in on the improvement of completely human antibody therapeutics, declared today that the organization will introduce the refreshed break information from the continuous stage Ib trial of olinvacimab and pembrolizumab combination therapy in metastatic triple-negative breast cancer (mTNBC) patients at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020) occurring for all intents and purposes over December 8-11, 2020.

Positive data from the progressing security and tolerability study will feature wellbeing and certain viability information including ORR (Overall Response Rate) and DCR (Disease Control Rate) from 11 patients diagnosed with mTNBC.

"We are excited to present highly encouraging data from our ongoing trial in the biggest breast cancer symposium.  These data offer important insights into future development of the combo therapy," said Dr. Jin-San Yoo, CEO of PharmAbcine.

Spotlight

R3 Stem Cell International offers safe and effective stem cell therapy for Crohns Disease and Ulcerative Colitis.

Spotlight

R3 Stem Cell International offers safe and effective stem cell therapy for Crohns Disease and Ulcerative Colitis.

Related News

MEDICAL

Agilent Announces Collaboration with APC on Real-Time Process Monitoring

Agilent Technologies | May 31, 2022

Agilent Technologies Inc. (NYSE: A) today announced a collaboration agreement with APC Ltd., in which the companies commit to working towards combining their technologies to provide unique workflows to customers that support automated process analysis via liquid chromatography (LC). Agilent has selected to partner with APC, a provider of innovative small molecule and large molecule process design and process development solutions. Both APC and Agilent pursue similar goals, which are focused on helping customers in the biopharmaceutical and pharmaceutical industry to improve the human condition and to delivering life-changing drugs to market faster and more efficiently. The collaboration between the companies leverages their complementary strengths to develop specific workflows, which bridge the gap between the analytical and process solutions. We are delighted to be collaborating with APC on a solution for real-time/automated process monitoring, Adapting our analytical capabilities to support online process monitoring requirements reflects the current trend within the pharma and biopharma industry towards continuous manufacturing and helps our mutual customers to develop higher quality drugs faster.” Stefan Schuette, vice president and general manager of Agilent’s Liquid Phase Separations Division. Agilent is a leader in the analytical lab with a comprehensive portfolio of analytical equipment for the biopharma and pharma industry, This collaboration leverages our complementary strengths and ultimately provides even better services and technologies to our customers by giving them greater insights into, and control of, their processes.” Damian Connolly, Analytical Lead at APC. The results obtained during the collaboration will be shared with customers via applications notes and joint webinars, which will also showcase the recently launched InfinityLab Online LC and InfinityLab Bio LC portfolio from Agilent. These new product offerings and the collaboration with APC ensure a leading position in the trend towards continuous manufacturing, process analytical technology (PAT), and real-time release testing (RTRT) in the biopharmaceutical and pharmaceutical industry. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide.

Read More

INDUSTRIAL IMPACT

Arctic Vision Announces First Patient Enrolled in Phase III Clinical Trial of ARVN003 for Presbyopia

Arctic Vision | July 05, 2022

Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced that the first patient has been enrolled in a Phase III clinical study evaluating ARVN003, a proprietary pilocarpine formulation leveraging its micro dosing platform Optejet®, as a treatment to temporarily improve vision in adults with presbyopia in China. The Phase III study is double-masked, placebo-controlled, randomized, and multicenter trial evaluating the efficacy and safety of ARVN003 in achieving temporary improvement of vision in adults with presbyopia. It is the first clinical trial approved in China for presbyopia drugs and Arctic Vision's study marks the first patient enrollment in a Phase III clinical trial for presbyopia drugs in China. Presbyopia is a physiological condition that makes it difficult to read and work in near distance. It is caused by the hardening of the lens and weakening of the ciliary muscle and often occurs with aging. Pre-presbyopia typically affects people between the ages of 35 and 45; early presbyopia affects people between the ages of 45 and 52; and late presbyopia, also known as absolute presbyopia, affects people over the age of 52. Today, nearly a quarter of the world's population is affected by presbyopia. With China's rapidly ageing population, the nation is seeing a year-on-year increase in the number of people suffering from presbyopia. Latest data revealed more than 390 million people in China are diagnosed with presbyopia in 2021. Current treatment options for presbyopia include presbyopic reading glasses, contact lenses and surgery. However, due to limited treatment options and inadequate scientific understanding of the disease, many presbyopia patients in China do not receive intervention or vision correction in time. Untreated and escalated, presbyopia adversely impacts vision, quality of work and life, and the psychological well-being of middle-aged and elderly people. It might also increase financial burden on families and society. Professor Jia Qu, the Principal Investigator and renowned leader in China's ophthalmology sector – President of Eye Hospital of Wenzhou Medical University said, "With China's rapidly aging population and a growing number of younger presbyopia patients, there is exponential demand for effective, safe, and convenient presbyopia treatments. We are excited to lead China's first clinical study of presbyopia medication and look forward to the approval of ARVN003 in the near future." "ARVN003's significant clinical progress is encouraging. This clinical achievement follows the successful dosing of the first DME patient in Asia with is testimony of the strength of Arctic Vision's proprietary microdose array print technology in the public eye health sector. We strive to make ARVN003 the first approved presbyopia drug in China, and benefit more presbyopia patients with innovative and diverse treatment options that will help them see and live better." Dr. Qing Liu, Co-Founder and Chief Medical Officer at Arctic Vision Arctic Vision obtained an exclusive license in August 2020 for the development and commercialization of ARVN003 in Greater China and South Korea from Eyenovia, a U.S.-based clinical-stage biopharma company. In May 2021, Eyenovia announced positive results from the first Phase 3 MicroLine study, VISION-1, in the U.S. In that trial, the primary endpoint was achieved with MicroLine 2% statistically superior to placebo, determined by improvement in high contrast binocular distance corrected near visual acuity measured in low light conditions two hours after treatment. About ARVN003 ARVN003 is a proprietary pilocarpine formulation leveraging microdosing platform Optejet® for the pharmacologic treatment for presbyopia. Pilocarpine ophthalmic solution is known to constrict the pupil and improve near-distance vision by creating an extended depth of focus through its small aperture effect. The administration of pilocarpine uses high-precision microdosing platform Optejet® to provide improvement in near vision while enhancing tolerability and usability. About Optejet® Optejet uses high-precision piezo-print technology to deliver approximately 8μL of drug, consistent with the capacity of the tear film of the eye. The volume of ophthalmic solution administered with the Optejet is 80% less than that delivered using conventional eye drops, thus reducing overdosing and exposure to drug and preservatives. Eyenovia's patented microfluidic ejection technology, MAP™ is designed for fast ocular surface delivery, where medication is dispensed as an array of microdroplets to the ocular surface in approximately 80 milliseconds, faster than the ocular blink reflex. Ease of use and successful delivery of medication by Optejet has been demonstrated in more than 85% of the attempts after basic training in a variety of clinical settings compared to 40 – 50% with conventional eyedroppers[i]. Additionally, its smart electronics and mobile e-health technology are designed to track and enhance patient compliance. About Arctic Vision Arctic Vision is a China-based ophthalmic biotech focusing on breakthrough therapies, with a leading portfolio covering pre-clinical stage to commercial stage products. Our vision is to provide innovative therapies in China, Asia and globally to address unmet clinical needs and benefit ophthalmic patients at large. Arctic Vision is supported by top-tier life sciences investors and led by an elite team of ophthalmic industry veterans with substantial regional and global experiences in R&D and commercialization of ophthalmic products.

Read More

DIAGNOSTICS

Zoetis to Complete Acquisition of Basepaws to Strengthen its Portfolio

Zoetis | June 27, 2022

Zoetis Inc. is the world's largest animal health company committed to providing medicine and vaccinations for pets and livestock. The company announced completing the acquisition of a privately held petcare genetics company, Basepaws, which offers early health risk assessments, genetic tests, and analytics to pet owners. The acquisition was first announced on June 7th. However, the financial terms of the purchase were not disclosed. Basepaws, founded by CEO Anna Skaya in 2017, provides genetic screening tools for the diagnosis of several pet diseases, health reports, and individualized breeds by identifying traits, potential hereditary conditions, and biomarkers. With the help of genetic insights from Basepaws, pet owners and doctors can better understand a pet's risk for the disease. This can result in more meaningful interactions and improve the chances of early identification and treatment of the disease. When we first met Basepaws CEO Anna Skaya and the team, we were immediately drawn to their passion for pets and the role that genetic testing and data analytics can have in advancing animal care – a purpose that drives us every day,The addition of Basepaws will enhance our portfolio in the precision animal health space and inform our future pipeline of petcare innovations. Working together, we can continue to provide veterinarians and pet owners with more comprehensive ways to proactively manage the health, wellness, and quality of care for their animals." Zoetis, CEO Kristin Peck.

Read More